Letrozol Sandoz

Letrozole, the active ingredient in Letrozol Sandoz, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of postmenopausal women with estrogen receptor‑positive breast cancer, helping to reduce tumor growth driven by estrogen.

GNH USA supplies Letrozol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company provides reliable sourcing, regulatory support, and logistics for hospitals, pharmacies and procurement teams across global markets.

Letrozol Sandoz, an aromatase inhibitor, is indicated for hormone‑dependent breast cancer in postmenopausal patients.

- Postmenopausal estrogen receptor‑positive breast cancer: reduces recurrence risk and slows disease progression. - Advanced or metastatic hormone‑receptor positive breast cancer: provides disease control when other endocrine therapies are unsuitable. - Adjuvant treatment of early‑stage hormone‑receptor positive breast cancer: improves disease‑free survival after surgery.

Letrozol Sandoz may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden warmth and sweating. - Joint pain: arthralgia or myalgia. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Osteoporosis or fractures: reduced bone density leading to breaks. - Severe liver injury: marked elevation of liver enzymes or hepatitis. - Allergic reactions: rash, itching, or anaphylaxis.

When prescribing Letrozol Sandoz, clinicians should observe several precautionary measures to minimise risk.

- Monitor bone health: assess baseline density and consider calcium/vitamin D supplementation. - Evaluate liver function: perform baseline tests and repeat periodically. - Check lipid profile: monitor cholesterol levels during therapy. - Assess cardiovascular risk: be cautious in patients with history of thromboembolic disease. - Avoid use in pregnancy: Letrozole is contraindicated in pregnant women (Category X). - Store at ambient temperature: keep below 25 °C in original container, protect from moisture and light.

Letrozol Sandoz can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce letrozole plasma levels. - Estrogen‑containing therapies (e.g., hormone replacement): counteract aromatase inhibition.

Moderate Interactions (Monitor Closely): - CYP2A6 inhibitors (e.g., fluvoxamine): may increase letrozole exposure. - Anticoagulants (e.g., warfarin): monitor INR as estrogen reduction can affect clotting. - Tamoxifen: concurrent use may diminish therapeutic effect.